D'ALIBERTI DEBORAH
Pubblicazioni
Elli, E., Mauri, M., D’Aliberti, D., Crespiatico, I., Fontana, D., Redaelli, S., et al. (2024). Idiopathic erythrocytosis: a germline disease?. CLINICAL AND EXPERIMENTAL MEDICINE, 24(1) [10.1007/s10238-023-01283-y]. Dettaglio
Crespiatico, I., Zaghi, M., Mastini, C., D'Aliberti, D., Mauri, M., Mercado, C., et al. (2024). First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis. BLOOD [10.1182/blood.2023021349]. Dettaglio
Aroldi, A., Angaroni, F., D’Aliberti, D., Spinelli, S., Crespiatico, I., Crippa, V., et al. (2023). Characterization of SARS-CoV-2 Mutational Signatures from 1.5+ Million Raw Sequencing Samples. VIRUSES, 15(1) [10.3390/v15010007]. Dettaglio
Zaghi, M., Banfi, F., Massimino, L., Volpin, M., Bellini, E., Brusco, S., et al. (2023). Balanced SET levels favor the correct enhancer repertoire during cell fate acquisition. NATURE COMMUNICATIONS, 14(1) [10.1038/s41467-023-39043-x]. Dettaglio
Mastini, C., Campisi, M., Patrucco, E., Mura, G., Ferreira, A., Costa, C., et al. (2023). Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma. SCIENCE TRANSLATIONAL MEDICINE, 15(702), 1-17 [10.1126/scitranslmed.abo3826]. Dettaglio